BBIO Price Prediction Next Week
BBIO Stock Price Prediction and Recommendation
Technical Analysis:
- RSI (14): 32.42 (oversold territory, potential for reversal)
- MACD: -0.19 (slightly bearish, but signal line is above MACD line, indicating some bullish momentum)
- SMA: Trading below 20, 50, and 200-day moving averages (bearish trend)
- Recent Price Action: Slight uptick in pre-market trading, indicating short-term positivity
Fundamental Analysis:
- Analyst Ratings: Strong Buy consensus with price targets of $45 (J.P. Morgan) and $95 (Cantor Fitzgerald)
- Insider Activity: Negative sentiment with 33 insiders selling shares recently
- Financials: P/E ratio of -11.09, indicating potential undervaluation or negative earnings
- Recent News: Merger with Helix Acquisition Corp. II expected to generate $550M in gross proceeds, positive catalyst
Price Prediction and Recommendation:
Based on the analysis, BBIO is expected to trade at $34.50 next week. The stock is oversold and due for a bounce, but the overall trend remains bearish. The merger news provides some upside potential, but without strong volume, the rally may be limited.
Recommendation: Sell BBIO at $34.50 as the upside is limited, and the stock may face resistance around $35.
BBIO Similar Chart Price Prediction
The price of BBIO is predicted to go up -6.46%, based on the high correlation periods with ENB. The similarity of these two price pattern on the periods is 92.83%.
BBIO
ENB
Down: -6.46%Similarity: 92.83%
BBIO Revenue Forecast
BBIO EPS Forecast
BBIO FAQs
What is BBIO revenue forecast for next quarter？
BBIO Analyst's Forecast
David Lebowitz
Citigroup
Strong Buy
2025-02-21
Price Target
$45 → $49
Upside
+32.25%
Citi raised the firm's price target on BridgeBio to $49 from $45 and keeps a Buy rating on the shares following the Q4 report. As of mid-February, 1,028 unique Attruby scripts had been written by 516 distinct prescribers since the therapy was approved by the FDA last November, the analyst tells investors in a research note. The firm says these numbers suggest strong initial physician interest in the drug. Beyond Attruby, BridgeBio's busy pipeline remains on track with two Phase 3 readouts in the second half of 2025, adds Citi.
Josh Schimmer
Cantor Fitzgerald
Buy
2025-02-21
Price Target
$95
Upside
+156.41%
Greg Harrison
Scotiabank
Buy
2025-02-21
Price Target
$49 → $52
Upside
+40.35%
